May 23, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Leukemia and Lymphoma

» Advanced search

Paper of the Month - September, 2011

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


0 rating

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.

Jiang Q, Xu LP, Liu DH et al.

There are few comparative studies to help guide treatment in accelerated-phase chronic myeloid leukemia (AP-CML). The main treatment choice is between a tyrosine kinase inhibitor (TKI)-based approach such as imatinib versus an allogeneic hematopoietic stem cell transplant (alloHSCT). The authors designed a cohort study to explore the relative merits of these treatment approaches in a single center based on a 9-year follow-up.

Please login or register to continue reading this article

View Archive »


ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. - May, 2012
Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. - April, 2012
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the Phase 3 randomised ENESTnd trial. - March, 2012
[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. - February, 2012
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. - January, 2012
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA - December, 2011
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation - November, 2011
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, Phase 2 trial - October, 2011
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. - September, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients - August, 2011
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure - July, 2011
Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia - June, 2011
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions - May, 2011
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. - April, 2011
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. - March, 2011
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized Phase III trial GOELAMS-LTP95. - February, 2011
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a Phase 3, randomised, non-inferiority trial. - January, 2011
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. - December, 2010
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. - November, 2010
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. - October, 2010
Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy - September, 2010
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma - August, 2010
Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma - July, 2010
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era - June, 2010
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma - May, 2010
Results of a Phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. - April, 2010
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma - March, 2010
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia - February, 2010
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia - January, 2010
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy - 2009
Autologous stem-cell transplantation in patients with HIV-related lymphoma - 2009
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience - 2009
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry - 2009
B-cell clones as early markers for chronic lymphocytic leukemia. - 2009
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. - 2009
Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. - 2009
Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB96 international study. - 2009
Longitudinal changes in Obesity and Body Mass Index Among adult survivors of Childhood Lymphoblastic Leukemia: a report from the childhood cancer survivor study. - 2009
Childhood leukemia in relation to radio frequency electromagnetic fields in the vicinity of TV and radio broadcast transmitters. - 2009
Phase III study of R-CVP compared with cyclosphosphamide, vincristine, and prednisone alone in patients with previously and treated advanced follicular lymphoma. - 2009

READER POLL

What do you consider to be the most exciting advances in therapeutics research in myeloid leukemia at present?

Junctional peptide vaccines
Tumor-based or primed dendritic cell-based vaccines
Novel vascular-disrupting or antiangiogenic agents
Small molecule inhibitors of the FLT3 kinase
Other

WEB LINKS

Original article

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 23, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Leukemia and Lymphoma » Advanced search